Division of Dockets Management
U.S. Food and Drug Administration
Department of Health and Human Services Room1061, HFA-305
5630 Fishers Lane
Rockville, MD 20852

Docket Number: FDA-2024-P-0422

ANDA Suitability Petition for Folic Acid Oral Solution, 0.1 mg/mL and 1 mg/mL.

Dear Sir/Madam,

Reference is made to the submission dated January 11, 2024, seeking permission to file an ANDA for Folic Acid Oral Solution, 0.1 mg/mL and 1 mg/mL.

Reference is also made to the e-mail from Kim-Yen Nguyen dated January 24, 2024, requesting to submit the information as an amendment to the ANDA Suitability Petition to the Division of Dockets Management, for the Agency to complete the review of the petition:

1. ***You are requesting that the FDA permit the filing of an Abbreviated New Drug Application (ANDA) under an approved suitability petition under section 505(j)(2)(C) of Federal Food, Drug, and Cosmetic Act ("the Act") for a change in dosage form. This type of change is subject to the pediatric assessment requirements imposed by the Pediatric Research Equity Act (PREA) as amended in 505B(a)(5) and 505B(e)(2)(B)(ii) of the Act. To request a waiver of the requirement to submit pediatric assessments, please include in your waiver the statutory reason(s) for requesting a waiver, including reference to the applicable statutory authority. The request should also include evidence that the request meets the statutory reason(s) for waiver. For additional information, please refer to draft guidance for industry on Pediatric Drug Development: Regulatory Considerations – Complying With the Pediatric Research Equity Act and Qualifying for Pediatric Exclusivity Under the Best Pharmaceuticals for Children Act (May 2023) which replaces the draft guidance for industry How to Comply With the Pediatric Research Equity Act.***

Petitioner Response:

The petitioner is submitting the request for waiver of pediatric studies with this response as summarized below.

Applicability of Pediatric Research Equity Act:

This petition is being submitted in support of a new dosage form for use in accordance with the conditions prescribed in the approved labeling for the reference listed drug. Therefore, the Petitioner relies on the established safety and efficacy of the Reference Listed Drug. As indicated

in the request for waiver of pediatric studies, the proposed dosage form does not encompass a new indication or dosing regimen or any other eligibility criteria for the conduct of pediatric studies. Therefore, the product included in this petition is exempt from the requirement for a pediatric assessment.

The petitioner's request meets the statutory reason (Section 505(B)(a)(5)(A)(i) of the FD&C Act (21 U.S.C. 355c(a)(5)(A)(i))) for waiver based on the rationale provided in the request for waiver of pediatric studies.

Sincerely,
For Method Pharmaceuticals LLC.

Scott Tucker

Scott Tucker
Chief Executive Officer

REQUEST FOR WAIVER OF PEDIATRIC STUDIES

Product Name: Folic Acid Oral Solution, 0.1 mg/mL and 1 mg/mL

Applicant: Method Pharmaceuticals LLC

Indication:

- Treatment of megaloblastic anemias

Pediatric Age Group (s) included in this request for waiver:

Method Pharmaceuticals LLC requests a waiver per indication and age group as stated below.

Indication	Age Group		
	0-2 years	>2-5 years	6-17 years
Treatment of megaloblastic anemias	Full Waiver*		

*The Petitioner relies on the established safety and efficacy of the Reference Listed Drug

Statutory Reason(s) for waiving pediatric assessment requirements:

Age group	Indication	Statutory Reason	Reference of Statutory Authority
All age groups	Treatment of megaloblastic anemias	Necessary studies are impossible or highly impracticable	Section 505B(a)(5)(A)(i) of the FD&C Act (21 U.S.C. 355c(a)(5)(A)(i)).

Supporting Evidence for Statutory Reason(s) for Pediatric Assessment Waiver Request:

The petitioner's request meets the statutory reason for waiver as indicated above and as justified below:

- The proposed Folic Acid Oral Solution does not pose a Safety or Effectiveness risk because the proposed strengths are included in the recommended product doses stated in the approved labeling of the referenced listed drug. The active ingredient, dose, indication, route of administration and dosing regimen of the proposed strengths are the same as for the reference listed drug, Folic Acid Tablets, approved under ANDA A080680.

- The Therapeutic Equivalence Evaluation code for the reference listed drug (ANDA 080680) is AA (See Attachment 1). Per the FDA Orange Book Preface (https://www.fda.gov/drugs/development-approval-process-drugs/orange-book-preface), an AA rating is *"for those active ingredients or dosage forms for which no* in vivo bioequivalence *issue is known or suspected, the information necessary to show bioequivalence between pharmaceutically equivalent products is either presumed and considered self-evident (based on other information in the application for some dosage forms (e.g., solutions)), or satisfied by a showing that an acceptable in vitro approach is met."* All oral Folic acid 1 mg tablets currently approved by FDA and not discontinued have 'AA' Therapeutic Equivalence Evaluation codes, indicating that the products are not subject to in vivo bioequivalence issues (see below).

RX	FOLIC ACID	FOLIC ACID	A040625	TABLET	ORAL	1MG	AA		RS	AMNEAL PHARMACEUTICAL
RX	FOLIC ACID	FOLIC ACID	A211064	TABLET	ORAL	1MG	AA			ATHEM HOLDINGS LLC
RX	FOLIC ACID	FOLIC ACID	A202437	TABLET	ORAL	1MG	AA			CADILA PHARMACEUTICALS LTD
RX	FOLIC ACID	FOLIC ACID	A090035	TABLET	ORAL	1MG	AA			CHARTWELL MOLECULAR HOLDINGS LLC
RX	FOLIC ACID	FOLIC ACID	A040796	TABLET	ORAL	1MG	AA			LEADING PHARMA LLC
RX	FOLIC ACID	FOLIC ACID	A204418	TABLET	ORAL	1MG	AA			NUVO PHAMACEUTICALS INC
RX	FOLIC ACID	FOLIC ACID	A091145	TABLET	ORAL	1MG	AA			QINGDAO BAHEAL PHARMACEUTICAL CO LTD
RX	FOLIC ACID	FOLIC ACID	A080680	TABLET	ORAL	1MG	AA	RLD	RS	WATSON LABORATORIES

- The proposed solution product facilitates dosing of the product per the current approved labeling for the RLD, as outlined in Table 2 of the suitability petition under "Proposed Indications and Usage". The United States Pharmacopeia (USP) includes a compounded Folic Acid oral solution monograph, presumably for the same reason i.e. facilitating administration of variable doses of the drug (see Attachment 2).
- The fact that folic acid is already in solution ensures systemic availability of the active ingredient given that there is no initial dissolution step, unlike in a tablet product.

Sincerely,
For Method Pharmaceuticals LLC.

Scott Tucker

Scott Tucker
Chief Executive Officer